FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

GSKCONS

10,732.6
+0 (0%)
Updated 03:59 15/04 IST

GSKCONS Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for GSKCONS
Disclaimer
0% Bullish
0% Bearish

GSKCONS Buy or Sell - Brokerage Reports

No. of reports in last year
6
No. of analysts
3
Average Consensus Forecast
8537.33
Consensus Potential
-26.59%
See GSKCONS Share Price Targets >>

GSKCONS Ratings

Long term GSKCONS rating by FrontPage users
3.6/5 (5 Ratings)
Find answers to all your questions on live GSKCONS message board: Is GSKCONS buy or sell? Should I buy GSKCONS shares? Why are GSKCONS shares falling? Should I invest in GSKCONS stock?

  1. Home
  2. GSKCONS Forum

GSKCONS Share Price Discussion

N
Reputation: 4,282 • Jul 22 3:51 AM
RBI has to come out with guidelines for banks’ moratorium books: Hemang Jani
Confusion over Axis moratorium book as the bank showed it was down from 22% to 9%, but June figures show the actual figure could be 15%.
The Economic Times
Like
Reply
N
Reputation: 4,282 • Jul 5 3:26 AM
Glaxo, Sanofi near 500 million pound UK vaccine deal: Times
Money would be paid in stages as the vaccine progresses, with final payment made on delivery.
The Economic Times
Like
Reply
N
Reputation: 4,282 • Jun 10 1:41 AM
Johnson & Johnson to begin human trials of COVID-19 vaccine in the second half of July
J&J's study will test the vaccine against a placebo and assess the shot's safety and immune response in 1,045 healthy people aged 18 to 55 years, as well as those 65 years and older. The trial will take place in the United States and Belgium.
The Economic Times
Like
Reply
N
Reputation: 4,282 • Apr 16 1:18 AM
These stocks found favour with mutual fund in March; do you own any?
In March, maximum MoM change in terms of value was seen in Tata Consumer, HUL, Dr. Reddy’s Labs, HPCL
Moneycontrol
Like
Reply
N
Reputation: 4,282 • Apr 15 4:08 AM
Coronavirus pandemic | Sanofi, GSK come together to develop vaccine for COVID-19
As per the partnership, France-based Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology.
Moneycontrol
Like
Reply
N
Reputation: 4,282 • Apr 8 12:48 PM
Hot Stocks | Three pharma stocks to bet on in the short term
On the higher side, 8,850 should act as an immediate hurdle for Nifty, above which short-covering can get extended and Nifty can move towards 9,200 levels as well.
Moneycontrol
Like
Reply
T
Reputation: -5,439 • Mar 26 5:44 AM

*GSK CONSUMER RS 18.39 CRS NSE BLOCK TRADE; FOR~ 20011 SHARES, AT RS 9189*
Like
Reply
R
Reputation: 1,179 • Feb 12 11:16 AM

Twitter

GSKCONS - 597699
GlaxoSmithkline Consumer Healthcare Ltd
ShortTerm Breakout
CupHandle Pattern
Debt to equity: 0.00
Profit growth 3Years: 12.69 %
maintaining a healthy dividend payout of 44.94% https://t.co/bVUSF3yvDH
1
Reply
D
Reputation: 19,879 • Feb 8 12:00 PM

Prabhudas Lilladher target on GSKCONS
Date: 07-Feb-20 Broker: Prabhudas Lilladher Price @ Call: 9229.85 Target: 9377 Recommendation: HOLD
Like
Reply
N
Reputation: 4,282 • Feb 6 2:53 AM
GSK Consumer Healthcare Q3 profit up 25% to Rs 276.63cr
The total income of the company rose to Rs 1,274.90 crore as against Rs 1,241.07 crore, GlaxoSmithkline Consumer Healthcare said in a filing to BSE.
Moneycontrol
Like
Reply

BRIEF-India's Glaxosmithkline Consumer Healthcare Dec Quarter Profit Rises - Reuters
06-Feb-2020 04:03:54 PM
Feb 6 (Reuters) - GlaxoSmithKline Consumer Healthcare Ltd GLSM.NS:
DEC QUARTER PROFIT 2.77 BILLION RUPEES VERSUS PROFIT OF 2.21 BILLION RUPEES LAST YEAR
CONSENSUS FORECAST...
Read more...
1
Reply
D
Reputation: 19,879 • Nov 14, 2019 7:00 AM

Nirmal Bang target on GSKCONS
Date: 11-Nov-19 Broker: Nirmal Bang Price @ Call: 8891.88 Target: 9200 Recommendation: ACCUMULATE
Like
Reply
D
Reputation: 19,879 • Nov 10, 2019 5:00 AM

Prabhudas Lilladher target on GSKCONS
Date: 08-Nov-19 Broker: Prabhudas Lilladher Price @ Call: 9053.2 Target: 9144 Recommendation: HOLD
Like
Reply
T
Reputation: -5,439 • Nov 8, 2019 2:18 AM

GlaxoSmithKline Consumer Healthcare (Q2, YoY) Revenue rose 5.7 percent to Rs 1,345.1 crore. Net profit rose 25.3 percent to Rs 345.3 crore. Ebitda rose 11.9 percent to Rs 395.8 crore. Margin stood at 29.4 percent versus 27.8 percent.
Like
Reply
U
Reputation: 563 • Nov 8, 2019 1:43 AM
Like
Reply

GSK Cons – Q2 FY20 (Unaudited – Cons.)
Share price – 9,239
Total revenue from operations at 1,345 Cr
1,272 Cr (5.72%) YoY | 1,194 Cr (12.62%) QoQ
Half year revenue: 2,539 Cr Vs. 2,379 Cr (6.72%)
Net Profit of 345.31 Cr
275.49 Cr (25.43%) YoY 248.08 (39.17%) QoQ
H...
Read more...
Like
Reply
U
Reputation: 563 • Oct 23, 2019 1:14 AM
Like
Reply
N
Reputation: 4,282 • Sep 24, 2019 4:48 AM
'Consumer staples may see 0-18% earnings growth but unlikely to pass on tax-cut benefits'
According to Kotak Institutional Equitie , companies under its universe may see 0-18 percent earnings growth in the current financial year.
Moneycontrol
Like
Reply
N
Reputation: 4,282 • Sep 23, 2019 3:58 AM
Britannia, Colgate, ITC, UBL, HUL gain over 6% after cut in corporate tax
Emkay upgraded Britannia and Colgate to buy from hold, while ITC and United Spirits to hold from sell.
Moneycontrol
Like
Reply
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • GSKCONS - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization30,336.2
    Enterprise Value26,238.86
    Price to Earnings36.62
    Price to Book Value7.41
    Return on Capital Employed0.31
    Return on Equity0.2
    Face Value10
    Dividend Yield0.01
  • GSKCONS - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    7-Feb-20Prabhudas LilladherHold9,377
    11-Nov-19Nirmal BangAccumulate9,200
    8-Nov-19Prabhudas LilladherHold9,144
    6-Aug-19Prabhudas LilladherHold7,872
    6-Aug-19Nirmal BangBuy7,700
    GSKCONS Brokerage Price Target
  • GSKCONS Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Apr 1510310108501031010732.6
    Apr 131045010566.41012010236.3
    Apr 9108781087810141.1510356.05
    Apr 81059011296.310504.5510639.3
    Apr 7966010700966010593.4
  • GSKCONS Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹9,369.55
    30 Day Moving Average₹9,403.62
    50 Day Moving Average₹9,375.99
    100 Day Moving Average₹9,007.06
    200 Day Moving Average₹8,556.47
  • GSKCONS - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue4,3173,986.460.08
    Operating Profit884833.490.06
    Profit Before Tax1,0741,010.410.06
    Net Income700656.680.07
  • GSKCONS - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds4,0953,4850.18
    Total Liabilities1,9731,9540.01
    Total Assets6,0685,4390.12
  • GSKCONS - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity723622.490.16
    Cash from Investing Activity-446-621.75-0.28
    Cash from Financing Activity-363-361.490
    Net Cash Flow-87-360.75-0.76
  • GSKCONS - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.130.13
    Return on Equity0.20.21
    Return on Capital Employed0.310.32
  • GSKCONS - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in RevenueNA
    3 Year CAGR Growth in Operating Profit0.21
    3 Year CAGR Growth in EBIDTA0.2
    3 Year CAGR Growth in Net Income0.2
    3 Yr CAGR Growth - Diluted EPS0.2
  • GSKCONS - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.35
    5 Year CAGR Growth in Operating Profit0.54
    5 Year CAGR Growth in EBIDTA0.66
    5 Year CAGR Growth in Net Income0.6
    3 Yr CAGR Growth - Diluted EPS0.6
  • GSKCONS - Recent News

    keyboard_arrow_down
    NewsBot
    Jul 22 3:51 AM
    RBI has to come out with guidelines for banks’ moratorium books: Hemang Jani
    The Economic Times
    NewsBot
    Jul 5 3:26 AM
    Glaxo, Sanofi near 500 million pound UK vaccine deal: Times
    The Economic Times
    NewsBot
    Jun 10 1:41 AM
    Johnson & Johnson to begin human trials of COVID-19 vaccine in the second half of July
    The Economic Times
    NewsBot
    Apr 16 1:18 AM
    These stocks found favour with mutual fund in March; do you own any?
    Moneycontrol
    NewsBot
    Apr 15 4:08 AM
    Coronavirus pandemic | Sanofi, GSK come together to develop vaccine for COVID-19
    Moneycontrol
    NewsBot
    Apr 8 12:48 PM
    Hot Stocks | Three pharma stocks to bet on in the short term
    Moneycontrol
    NewsBot
    Feb 6 2:53 AM
    GSK Consumer Healthcare Q3 profit up 25% to Rs 276.63cr
    Moneycontrol
    NewsBot
    Sep 24, 2019 4:48 AM
    'Consumer staples may see 0-18% earnings growth but unlikely to pass on tax-cut benefits'
    Moneycontrol
    NewsBot
    Sep 23, 2019 3:58 AM
    Britannia, Colgate, ITC, UBL, HUL gain over 6% after cut in corporate tax
    Moneycontrol
    NewsBot
    Aug 7, 2019 11:03 AM
    Hold GlaxoSmithKline Consumer Healthcare target of Rs 7931: Sharekhan
    moneycontrol.com
  • GSKCONS - Related Communities

    keyboard_arrow_down
    Jubilant Foodworks Ltd. NSE: JUBLFOOD...
    Britannia Industries Ltd. NSE: BRITAN...
    Nestle India Ltd. NSE: NESTLEIND | BS...
    Future Consumer Ltd. NSE: FCONSUMER |...
    Godrej Agrovet Ltd. NSE: GODREJAGRO |...
    Parag Milk Foods Ltd. NSE: PARAGMILK ...
    kwality Ltd. NSE: KWALITY | BSE: 5318...
    Apex Frozen Foods Ltd. NSE: APEX | BS...
    Vadilal Industries Ltd. NSE: VADILALI...
    ADF Foods Ltd. NSE: ADFFOODS | BSE: 5...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020